HOME >> MEDICINE >> NEWS
Phase II study shows combination improves survival of metastatic melanoma patients

ew blood vessels from forming and allows the chemotherapy to work.

Fifty-three patients were treated with carboplatin, weekly treatments of paclitaxel (Taxol) and biweekly bevacizumab. Researchers found that the treatment was well tolerated and prevented the tumor from spreading from eight to nearly 24 weeks.

The number of new melanoma cases has continued to rise at a rate of about 5 percent to 10 percent each year since the 1970s, Dr. Markovic says. Why" One cause, he says, is depletion of the ozone layer, but also, more cases are coming to light due to greater public awareness.

"The increase in incidence is a big worry, particularly when we still do not have an effective treatment. That's why this step, however small, is important," Dr. Markovic says.


'"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Jun-2007


Page: 1 2 3

Related medicine news :

1. GSK announces launch of largest ever Phase III trial in lung cancer treatment
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. Drug combination proves effective against myeloma in Phase I trial
4. Researchers present Phase 2 clinical results for Acologix AC-100
5. Positive results for ACRUXs lead product in US Phase 3 trial
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. GroPep starts Phase 1 infertility trial
8. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
9. Joint statement on Savvy Phase 3 trial in Ghana to test the effectiveness of Savvy Gel in preventing HIV
10. NIAID launches first Phase II trial of a global HIV/AIDS vaccine
11. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... , ... Clearwave is the leading provider in ... XT-series of touch screen terminals. Both companies will be showcasing their solutions at ... provider Posiflex is helping to bridge the gap between healthcare hardware and software ...
(Date:2/20/2017)... ... 20, 2017 , ... Best Doctors® and IBM today announced ... companies that want to help members of their workforce battling cancer. Through the ... Watson’s suite of oncology offerings for insights on cancer treatment options, ranging from ...
(Date:2/20/2017)... TX (PRWEB) , ... February 20, 2017 , ... Chuck ... of Sensory Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New ... and other special needs, the opportunity to experience the fun of visiting Chuck E. ...
(Date:2/19/2017)... ... 19, 2017 , ... Braun Industries will be participating as an exhibitor at ... take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center ... new ambulances on display. , “JEMS is a leader in EMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. ... reduce their regulatory burden? Pay dividends in enhanced and predictable product performance? ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Feb. 20, 2017 Research and Markets has ... Insights, Opportunity, Analysis, Market Shares & Forecast 2017 - 2022" ... ... nearly USD 2 Billion by the year end of 2022 growing ... Market growth can be attributed to factors such as ...
(Date:2/20/2017)... , Feb. 20, 2017   AT&T ... physicians diagnose and treat patients with cardiovascular disease ... wireless connectivity for ZywiePro, Zywie,s cardiac remote monitoring ... Control Center . AT&T and Zywie ... for those with the disease. The Internet of ...
(Date:2/20/2017)... 2017 Seal Shield LLC ( Jacksonville, ... mobile device management and disinfection, the ElectroClave™, to the ... in Orlando, Fla. from February ... have become commonplace in today,s healthcare landscape, but with ... concerns, including the disinfection and tracking of these devices.  ...
Breaking Medicine Technology:
Cached News: